Eicosanoids in experimental and human renal disease.

Area of Science:

• Nephrology
• Renal Physiology
• Immunology

Background:

• Renal prostaglandins and thromboxanes are potent autacoids influencing renal hemodynamics, salt/water balance, and immunity.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) can adversely affect renal function in patients with renal disease due to cyclooxygenase inhibition.

Purpose of the Study:

• To review the role of renal prostaglandins and thromboxanes in renal disease.
• To explore the therapeutic potential of prostaglandins and the adverse effects of their inhibition in various renal conditions.

Main Methods:

• Review of experimental evidence on renal prostaglandin and thromboxane production in renal disease models.
• Analysis of studies investigating cyclooxygenase inhibition and prostaglandin administration in renal disease.
• Examination of thromboxane synthesis inhibitors' efficacy in glomerular and other renal diseases.

Main Results:

• Renal prostaglandin and thromboxane production increases in several renal disease models.
• Cyclooxygenase inhibition can impair renal function, potentially by inhibiting vasodilator prostaglandins.
• Prostaglandin administration shows therapeutic promise in some renal diseases, especially immunologically mediated ones.
• Thromboxane inhibition has yielded disappointing results in glomerular disease but may benefit ureteric obstruction and transplant rejection.

Conclusions:

• Prostaglandins play a complex role in renal disease, with both protective and detrimental effects depending on the specific eicosanoid and disease context.
• While NSAIDs pose risks, prostaglandins themselves may be valuable therapeutic agents in specific renal conditions.
• Further research into modulating prostaglandin and thromboxane pathways could lead to novel treatments for renal disorders.